Today's Date: March 26, 2023
SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote   •   National University Receives 2023 Military Friendly® Gold Designation   •   Build community with shared future, create better world   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t   •   Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges   •   ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B   •   Philadelphia Works Names First Female Chief Operating Officer   •   SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los   •   GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office   •   Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail   •   30+ Health Leaders Explore Strategies to Ease Hospital-to-Home Patient Transitions   •   HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   Dr. Kelli Ward and Martha Boneta Fain join the advisory board of Legacy PAC, a partner of Veterans for Trump   •   Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference   •   DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio   •   SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI   •   Statement from the Chief Public Health Officer of Canada on World TB Day   •   ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting   •   Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates   •   AI-Powered Stylitics Launches Latest Platform with First-of-Its-Kind Automated Styling Technology for Retailers
Bookmark and Share

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings

PR Newswire

CINtec® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive

ELMWOOD PARK, N.J., Feb. 9, 2023 /PRNewswire/ -- BioReference® Health LLC, one of the largest full-service specialty laboratories in the United States, announced today it will be one of the first commercial laboratories to use offer the CINtec® PLUS Cytology test from Roche Diagnostics. CINtec PLUS Cytology is the only FDA-approved dual-stain triage test for patients who have a high-risk human papillomavirus (HPV) result. The test is commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Women's Health.

Based on a patient's individual risk level, healthcare providers use screening and triage tests to identify disease risk and establish appropriate healthcare management. Testing strategies that result in greater disease detection can help healthcare providers care for their patients and lead to improved clinical outcomes. CINtec PLUS Cytology can reduce the number and frequency of follow-up visits, while providing patients clearer answers and greater test result certainty.

CINtec PLUS Cytology uses dual-stain biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. The presence of both biomarkers, p16 and Ki-67, within the same cell is a strong indicator that an HPV infection is undergoing oncogenic transformation. BioReference will offer the test to women aged 30-65 as a reflex when the cytology result is NILM and the hrHPV result is positive with cobas® HPV test. The dual-stain biomarker test allows a treating healthcare provider to more accurately and quickly assess the risk for cervical pre-cancer in patients.

"We're proud to be offering our patients more clarity and information that can empower them to better manage and understand their health," said Ellen Beausang, Chief Commercial Officer, BioReference. "This test allows healthcare providers to act appropriatey and in a timely manner, because they're equipped with more accurate test results that can better assess a patient's risk of cervical cancer related to HPV."  

According to the Centers for Disease Control and Prevention (CDC), HPV is the most common sexually transmitted infection (STI). There are many different types of HPV and some types can cause health problems, including cervical cancer, which can take years or even decades to develop after a patient contracts HPV. However, not every HPV-positive woman will develop cervical cancer, and CINTec PLUS Cytology triage can determine a patient's individual risk level and if they would benefit from more immediate follow-up.

"We know that cervical cancer is one of the most preventable forms of cancer," said Tamera Paczos, MD, MS, FACP, FACOG, Vice President, Associate Chief Medical Officer, BioReference. "We're pleased to enhance our cervical cancer screening test offerings with this innovative new test that provides valuable information that can be used to determine which patients with positive high risk HPV and normal pap results may be at risk of harboring cervical pre-cancer."

About BioReference Health

BioReference® Health LLC, an OPKO Health, Inc. Company (NASDAQ: OPK), empowers confident healthcare decisions by prioritizing service, creating innovative solutions, and offering scientific expertise in oncology, urology, and women's healthHeadquartered in Elmwood Park, New Jersey, BioReference operates 10 laboratory facilities around the country, is in-network with the largest health plans in the United States and processes more than 12 million tests, annually. BioReference provides credible and tailored solutions for a variety of customers and patients, including medical practices small and large, hospitals and health systems, correctional institutions, government agencies, educational systems, and sport leagues. In addition to an extensive test menu with 99 percent of tests performed in-house, BioReference's differentiated offerings include large-scale health screening programs, on-demand mobile phlebotomy, and transformative business solutions that optimize laboratory management. For more information visit or on FacebookTwitterInstagram and LinkedIn.


Media Contact

Emily Smith 

Cision View original content to download multimedia:

SOURCE BioReference Health, LLC

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News